tiprankstipranks
Advertisement
Advertisement
Touchlight Amplifies Cost and Performance Case for Cell-Free DNA Platforms
PremiumPrivate CompaniesTouchlight Amplifies Cost and Performance Case for Cell-Free DNA Platforms
5d ago
Touchlight Highlights Enzymatic Circular DNA Platform for Next-Generation Gene Editing
Premium
Private Companies
Touchlight Highlights Enzymatic Circular DNA Platform for Next-Generation Gene Editing
5d ago
Touchlight Highlights Cell-Free DNA as Emerging Infrastructure for Gene and Viral Therapies
Premium
Private Companies
Touchlight Highlights Cell-Free DNA as Emerging Infrastructure for Gene and Viral Therapies
6d ago
Cell-Free DNA Platforms Positioned as Infrastructure for Gene and Viral Therapies
PremiumPrivate CompaniesCell-Free DNA Platforms Positioned as Infrastructure for Gene and Viral Therapies
9d ago
Touchlight Highlights Data Indicating Efficiency Gains in Lentiviral Vector Production
Premium
Private Companies
Touchlight Highlights Data Indicating Efficiency Gains in Lentiviral Vector Production
9d ago
Touchlight Leans on Cost, Performance Data to Bolster Cell-Free DNA and Gene-Editing Platforms
Premium
Private Companies
Touchlight Leans on Cost, Performance Data to Bolster Cell-Free DNA and Gene-Editing Platforms
12d ago
Touchlight Highlights mbDNA Platform for Non-Viral Gene Editing in HSPCs
PremiumPrivate CompaniesTouchlight Highlights mbDNA Platform for Non-Viral Gene Editing in HSPCs
15d ago
Touchlight Positions dbDNA™ Platform as Scalable Alternative for Genetic Medicine Manufacturing
Premium
Private Companies
Touchlight Positions dbDNA™ Platform as Scalable Alternative for Genetic Medicine Manufacturing
17d ago
Touchlight Deepens Cell-Free DNA Push With New Data, Expanded Capacity and Deal-Making Drive
Premium
Private Companies
Touchlight Deepens Cell-Free DNA Push With New Data, Expanded Capacity and Deal-Making Drive
19d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100